HD-OPM Archive
Topics › Nuts, fish, coffee, tea, cocoa & other foods

UK Biobank: 3 cups of coffee a day linked to 48% lower cardiometabolic multimorbidity

Louis Nervegna · Jun 22, 2025 · ♥ 12 reactions · 12 comments · original Facebook post
Nuts, fish, coffee, tea, cocoa & other foodsInsulin resistance & diabetes
AI summary & key facts

Louis shares a UK Biobank analysis (over 500,000 people, 11 years) in which three cups of coffee daily was associated with 48% lower new-onset cardiometabolic multimorbidity, and 200-300 mg of caffeine with 41% lower. Moderate caffeine was also linked to lower VLDL; this is observational data.

#coffeeHD #cvdHD #diabetesHD #strokeHD

Research cited

Regular consumption of moderate amounts of coffee and caffeine has been tied to significantly reduced risk of developing multiple cardiometabolic diseases, including type 2 diabetes, coronary heart disease, and stroke, according to recently published in the Journal of Clinical Endocrinology & Metabolism (doi:10.1210/clinem/dgae552). The study found that consuming three cups of coffee or 200-300 mg of caffeine per day is associated with a 48% lower risk of new-onset cardiometabolic multimorbidity —the coexistence of at least two cardiometabolic conditions.

The research analyzed data from the UK Biobank, which included over 500,000 participants aged 37-73 years over an 11 year period. After excluding those with existing cardiometabolic diseases, the findings were as follows:

*️⃣48% reduced risk of new-onset CM for individuals consuming three cups of coffee per day.
*️⃣ 41% reduced risk for those consuming 200-300 mg of caffeine per day.

The study also found that moderate caffeine intake was linked to lower levels of harmful very low-density lipoprotein.

The protective effect of caffeine from coffee and tea was observed across almost all stages of cardiometabolic multimorbidity development, suggesting the importance of coffee and caffeine in maintaining overall cardiometabolic health.

No photo description available.
← newer: PREVENTABLE: 20,000-person trial of atorvastatin 40 mg to prolder: Statins, especially with ezetimibe, lower Lp-PLA2, a plaque- →